TLR4 and necrotizing enterocolitis: An exciting and rather serendipitous discovery in the current work links our identification of this aminoglycoside scaffold (i.e., C34 and the closely related β-anomeric cyclohexyl analog C35) to the treatment of experimental NEC, a disease that we and others have shown to be mediated via TLR4 activation in mice and humans [26], [27].